HOECHST MARION ROUSSEL

iQure Pharma Appoints Former UCB Chief Medical Officer Iris Loew-Friedrich as Clinical and R&D Advisor

- iQure Pharma, a clinical-stage biotech company developing treatments for CNS disorders through glutamate balance restoration, has appointed Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor. - Loew-Friedrich brings over 30 years of global pharmaceutical leadership experience, having served as Executive Vice President, Chief Medical Officer, and Head of Development at UCB from 2008 to 2024. - Her leadership at UCB contributed to the regulatory approvals of multiple drugs including bimekizumab, rozanolixizumab, zilucoplan, brivaracetam, and romosozumab across U.S., EU, and international markets. - The appointment strengthens iQure's clinical development capabilities as the company advances its lead asset iQ-007, a first-in-class oral small molecule currently in Phase 1 development for treatment-resistant epilepsy.